Skip to main content
. Author manuscript; available in PMC: 2017 Feb 10.
Published in final edited form as: J Neuroimmunol. 2008 Jul 3;200(1-2):145–152. doi: 10.1016/j.jneuroim.2008.05.016

Fig. 1.

Fig. 1

The figure depicts the 17q11.2–q21 region (1.83 MB) with 1,508,243 bp gap between CCL1 and CCL5 and a 96,158 bp gap between CCL5 and CCL16. The lower part of the figure indicates the placing of markers in the phase I (open circles) (Vyshkina et al., 2005), phase II (open stars) (Vyshkina and Kalman, 2005) and present study (diamonds). Upper bars (striped) in the top part of the figure indicate MS-associated haplotypes in the phase I study and lower bars (dotted) indicate MS-associated haplotypes in the phase II study. Note the overlap in markers and haplotypes within the genes of CCL15 and CCL3. The main rational for the selection of the present markers was to include SNPs previously associated with MS, tagging SNPs and non-synonymous mutations in genes of interest.